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ABSTRACT
Background. In patients with a diagnosis of occult cer-
vical cancer made on a hysterectomy specimen after
surgery for a benign indication, lymph node assessment is
crucial to determine treatment. We aimed to compare
sentinel lymph node (SLN) mapping between patients with
postoperative diagnosis of occult cervical carcinoma and
patients with cervical cancer and uterus in situ.
Methods. A retrospective analysis of cervical cancer
patients International Federation of Gynecology and
Obstetrics (FIGO) stage IA–IIA disease undergoing
laparoscopic SLN mapping was performed. Patients were
divided into two groups: those with a diagnosis of occult
cervical cancer made on a hysterectomy specimen (group
1) and those with a diagnosis of cervical cancer and uterus
in situ (group 2). Tracers used for SLN mapping included
technetium-99m (99mTc), blue dye, and indocyanine green.
After detection and excision, the SLN was sent for frozen
section analysis, and the planned surgical procedure was
aborted in case of metastatic disease in favor of a
chemoradiotherapeutic treatment.
Results. Groups 1 and 2 included 9 and 62 patients,
respectively. Clinicopathologic characteristics were similar
among the two groups. Overall and bilateral detection rates
were 66.6 and 33.3 and 95.1 and 87 % in groups 1 and 2,
respectively (p\ 0.05). No false-negative SLNs were
identified in either group, with a negative predictive value
of 100 %.
Conclusions. SLN mapping in occult cervical cancer
patients has lower detection rates compared to patients with
uterus in situ. In these patients, proper management of their
disease has already failed before diagnosis, and additional
mistakes may definitely compromise attempts at cure.
The diagnosis of occult cervical cancer made on a
simple hysterectomy specimen after surgery for a benign
indication is an unpleasant yet not uncommon finding. This
clinical scenario leads to a decision management dilemma.
Some authors recommend that a radical parametrectomy
with systematic pelvic lymphadenectomy always be per-
formed.1,2 On the other hand, several retrospective studies
have identified a group of cervical cancer patients with
lesions smaller than 2 cm in diameter, without lympho-
vascular space involvement and with negative lymph
nodes, who are virtually at no risk of parametrial
involvement.3–5 Consequently, some authors recommend
avoiding a parametrectomy in these patients; a prospective
trial is currently randomizing patients with early stage
cervical cancer with these characteristics to a simple versus
a radical hysterectomy, both in conjunction with pelvic
lymphadenectomy.6–8 For patients with pathologic inter-
mediate risk factors (a combination of tumor size, depth of
stromal invasion, and lymphovascular space involvement)
or high-risk factors (cut through, or parametrial or lymph
node involvement), radiotherapy and chemoradiotherapy
are indicated.9–11
In either case, a lymph node assessment is indicated to
determine pathologic risk factors that can determine need
for adjuvant treatment. This is best performed laparo-
scopically to reduce surgical morbidity.12,13 There is
increasing evidence suggesting that sentinel lymph node
(SLN) biopsy may be safely integrated into the manage-
ment of early stage cervical cancer.14–16 There is much
experience with the use of blue dye and technetium-99m
(99mTc) as mapping techniques for SLN biopsy in cervical
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cancer, with an overall sensitivity and SLN detection rate
of over 90 %.17 More recently, indocyanine green (ICG)
has shown promising results in gynecologic oncology.18–22
After submucosal injection, tracers used for SLN mapping
are taken into the lymph ducts, through which they travel to
the SLN, which can then be identified and sampled.
It has been demonstrated that a history of cervical
conization does not influence detection rates, predictive
value, or the distribution of SLNs.23,24 To our knowledge,
SLN mapping for cervical cancer accidentally diagnosed
on a hysterectomy specimen has not yet been reported.
Several questions concerning this technique remain open:
Is the vaginal apex a valid surrogate of the cervix for tracer
injection? Have the surgical scars and inflammation pro-
cess altered the anatomic structures and disrupted the
lymphatic vessels to a point where the SLN mapping is no
longer reliable?
The aim of this study was to compare overall and
bilateral detection rates, false-negative rates, and localiza-
tion of SLNs in patients undergoing SLN mapping after
postoperative diagnosis of occult cervical carcinoma with
cervical cancer patients undergoing SLN mapping with
uterus in situ.
METHODS
A retrospective analysis of all cervical cancer patients
with International Federation of Gynecology and Obstetrics
(FIGO) stage IA–IIA disease undergoing laparoscopic SLN
mapping at the University Hospital, Bern, between April
2008 and July 2015 was performed. Demographic, clinical,
and pathologic data were retrieved from an electronic
database. Missing data were integrated by surgical reports
and clinical charts. Since January 2011, the data for all
patients receiving ICG SLN mapping were prospectively
collected. The study was approved by the institutional
review board. All patients signed informed consent. Cer-
vical cancer patients were then divided into two groups:
those with occult cervical cancer diagnosed on a hys-
terectomy specimen and undergoing laparoscopic SLN
biopsy with or without radical parametrectomy and sys-
tematic pelvic lymphadenectomy (group 1), and those with
a preoperative diagnosis of cervical cancer on punch
biopsy or conization and undergoing laparoscopic SLN
mapping with or without radical hysterectomy and sys-
tematic pelvic with or without para-aortic
lymphadenectomy (group 2).
Pretreatment evaluation consisted of collection of
medical history, physical examination, examination under
anesthesia, and positron emission tomography/computed
tomography scan. Magnetic resonance imaging of the
pelvis was performed to rule out parametrial invasion if the
clinical stage was unclear. From April 2008 until January
2011, SLN mapping was performed with a preoperative
99mTc injection and lymphoscintigram with fusion com-
puter tomogram (single-photon emission computed
tomography, SPECT) with or without intraoperative patent
blue dye injection. From January 2011 until July 2015,
SLN mapping was performed with intraoperative ICG
injection. No other significant changes in patients’ man-
agement occurred throughout the study period. For patients
undergoing 99mTc SLN mapping, 120 MBq of 99mTc was
injected into the quadrants of the cervix or in the anterior
and posterior wall of the vaginal stump on the day before
surgery. SPECT was performed to preoperatively locate the
SLNs. On the day of surgery, in the operating room, the
patient was injected in the cervix or in the vaginal stump
with 5 ml of patent blue dye in the quadrants. Under
gamma probe (Navigator; Autosuture) guidance and patent
blue dye visual guidance, the SLNs were laparoscopically
located and removed. For patients undergoing ICG SLN
mapping, 8 ml of ICG (Pulsion) was injected in the oper-
ating room immediately before laparoscopy. ICG was
injected in the quadrants of the cervix or in the anterior and
posterior wall of the vaginal stump. Two vials of ICG
(Pulsion) had been previously suspended with 10 ml of
sterile water. Under the visual guidance of fluorescent
light, and using a laparoscopic near-infrared fluorescent
optic device (Storz), the SLN was located and removed
(Fig. 1).
Excised SLNs were sent for frozen section analysis. In
cases of negativity for metastatic disease, the planned
surgical procedure was completed, including a full pelvic
lymphadenectomy. The radical procedure was aborted in
favor of concurrent chemoradiotherapy. In these cases, a
para-aortic laparoscopic lymphadenectomy was performed
in order to plan the extension of the radiation field. At final
histopathologic analysis, a complete ultrastaging with
immunohistochemistry was performed.
Demographic and clinicopathologic characteristics were
evaluated using basic descriptive statistics. Overall and
bilateral detection rates, false-negative rates, and negative
predictive value of SLN mapping in the two groups were
calculated and compared by Fisher’s exact test. The false-
positive rate was defined as 0. The overall detection rate
was calculated by the number of procedures in which at
least one SLN was identified divided by the total number of
procedures performed; the bilateral detection rate was
calculated by the number of procedures in which at least
one SLN was identified on each side of the pelvis divided
by the total number of procedures performed. A truly
positive SLN was defined as a positive SLN identified by
histopathologic techniques independent of regional lymph
node status. A false-negative SLN was defined as a nega-
tive SLN in combination with metastatic non-SLNs
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(NSLN). Additionally, localization of SLNs among the two
groups were compared by the Chi square test. Statistical
analyses were performed by R software 3.1.0. All p values
were two sided, and p values of \0.05 were considered
statistically significant.
RESULTS
In the study period, 71 patients diagnosed with cervical
cancer undergoing SLN mapping were identified. Of these,
9 patients were diagnosed with an occult cervical cancer
after having undergone a simple hysterectomy and were
referred to us for oncologic management (group 1). An
abdominal, vaginal, or laparoscopic hysterectomy had been
performed in 2, 3, and 4 patients, respectively. In every
case, the hysterectomy was simple and did not include any
parametrial resection. Median interval of time between the
two surgeries was 45 days (range 10–80 days). The
remaining 62 patients were diagnosed with cervical cancer
on punch biopsy or cervical conization (group 2).
Clinicopathologic characteristics did not differ signifi-
cantly among the two groups with regard to median age,
body mass index, and tumor diameter. Patients with occult
cervical carcinoma had an unusual histology and well-
differentiated tumors significantly more often than the
patients in group 2. The FIGO stage in patients in group 2
was IA, IB1, IB2, IIA1, and IIA2 in 6, 31, 13, 5, and 7
patients, respectively. Clinicopathologic characteristics are
summarized in Table 1.
SLN mapping was performed with 99mTc, 99mTc and
blue dye, and ICG in 22.2, 44.4, and 33.3 % and 3.2, 38.7,
and 58.1 % of patients in groups 1 and 2, respectively. SLN
mapping with ICG or a combination of 99mTc and blue dye
was performed significantly more often in patients in group
2.
A mean of 1 (range 0–4) and 3 (range 0–15) SLNs were
identified in groups 1 and 2, respectively. SLNs were located
along the external iliac basins, the obturator fossa, and the
common iliac basins in 33.3, 50, and 8.3 % and in 17, 58,
and 19 % of the cases in groups 1 and 2, respectively
(Fig. 2). No, overall and bilateral detection rates were 33.3,
66.6, and 33.3 % and 4.9, 95.1, and 87 % in groups 1 and 2,
respectively. Overall and bilateral detection rates were sig-
nificantly higher among patients in group 2 p = 0.02;
p = 0.0001). No false-negative SLNs were seen in either
group, with a negative predictive value of 100 %. No pos-
itive SLNs were identified in group 1, and one NSLN was
positive in a patient in whom SLN mapping failed to detect
any SLNs. Median number of NSLNs was 33 (range 24–46)
and 34 (range 0–80) for group 1 and 2 respectively. Data on
SLNs results are summarized in Table 2.
DISCUSSION
Because lymph node spread represents the most
important prognostic factor in early stage cervical cancer, a
systematic pelvic lymphadenectomy has been part of the
surgical treatment for the last 70 years.25 For 10 years,
SLN biopsy in cervical cancer has consistently recorded
good oncologic outcomes, and it is likely that in the near
future, it will be routinely applied in early stage tumors.5
The incidence of occult invasive cervical cancer is not well
established; however, Park et al. reported that 5.3 % of
patients with cervical cancer managed at their referral
center were diagnosed from a hysterectomy specimen after
the uterus was removed for another benign indication.26 In
our series, occult cervical cancer patients accounted for
12.7 % of the entire cohort of cervical cancer patients.
Both series show that although uncommon, the problem is
relevant, and physicians working in referral centers will
FIG. 1 a Laparoscopic view of a the vaginal stump in a patient who
was diagnosed with occult cervical cancer after a simple hysterec-
tomy was performed for a benign indication. Under visual guidance,
using a laparoscopic near-infrared optic device (Storz), the fluorescent
light can be followed until the SLN is identified. b Under visual
guidance, the SLN is identified on the right, medial to the external
iliac vessels
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FIG. 2 The SLNs were located
along the external iliac basins,
the obturator fossa, and the
common iliac basins in 33.3, 50,
and 8.3 % and in 17, 58, and
19 % of the cases in group 1 and
2 respectively
TABLE 1 Patient characteristics
Characteristic Group 1 (n = 9) Group 2 (n = 62) p
Age (year) median (range) 44.5 (37–78) 44 (25–72) 0.761
BMI (kg/m2), median (range) 24.7 (19.6–39.3) 24.1 (17.4–41.5) 0.278






Tumor diameter (mm), mean (range) 20 (3–60) 30 (2–80) 0.285
Histology n (%)
Squamous cell carcinoma 4 (44.4) 43 (69.4) 0.003
Adenocarcinoma 3 (33.3) 17 (27.4)
Clear cell carcinoma 1 (11.1) 0
Carcinosarcoma 1 (11.1) 0
Neuroendocrine tumor, n (%) 0 2 (3.2)
Time to second surgery in days, median (range) 47 (10–80) NA
Grade, n (%) 0.001
NA 1 (11.1) 4 (6.4)
1 2 (22.2) 0
2 2 (22.2) 37 (59.7)
3 4 (44.4) 21 (33.9)
BMI body mass index, FIGO International Federation of Gynecology and Obstetrics, NA not available
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have to manage this kind of patient. In these patients,
lymph node status represents the most important prognostic
factor driving oncologic decision making.
In our experience, SLN mapping seems to be feasible in
the setting of laparoscopic parametrectomy performed after
a simple hysterectomy, with an overall detection rate of
66 %. In the absence of the uterus and the cervix, the
vaginal vault represents the best tracer injection site for
SLN mapping, as upper vagina and cervix drain through
the same lymphatic routes via supraureteral, infraureteral,
and neural pathway to the parametria and to the pelvic and
para-aortic lymph nodes.27,28
In our series, both overall and bilateral detection rates in
the setting of occult cervical cancer status after simple
hysterectomy were significantly lower compared to those
recorded in patients who were injected in the cervix. This is
most likely related to postoperative scarring and inflam-
mation, which may clog or seal lymphatic vessels draining
the area. However, the degree to which these postsurgical
rearrangements affect SLN mapping is unclear and is likely
influenced by the technique used as well as by postopera-
tive events such as vaginal vault abscesses and
dehiscences. In our series, 2 patients did not map. One of
these patients presented with NSLN metastases, which has
been reported to be a variable negatively influencing the
identification of SLN due to occlusion of lymphatic
drainage.
In cutaneous melanoma, it is not unusual that a patient is
referred to a tertiary care center for management after a
wide local excision of the primary lesion has been per-
formed. In these cases, SLN mapping is feasible and does
not seem to be affected by the previous surgery unless an
extensive reconstruction of the primary excision site has
been performed.29–31 More recently, SLN mapping after a
previous excision of the primary vulvar cancer has been
shown to be feasible and accurate.32 In the literature, at
least two studies have reported on cervical cancer SLN
mapping after cervical conization.23,24 In these series, a
previous conization did not seem to affect the outcome of
SLN mapping. However, compared to a conization or a
wide local excision, a simple hysterectomy not only
removes the organ that is usually injected with the tracer
but is also responsible for a greater disruption of the pelvic
anatomy.
The tracers used influence the detection rates in SLN
mapping, among other factors. Compared to 99mTc, the
combination of 99mTc and blue dye has been associated
with higher detection rates. More recently, we were able to
show that the use of ICG improves bilateral detection rates
of SLN mapping in cervical cancer patients compared to
TABLE 2 SLN mapping data
Characteristic Group 1 (n = 9) Group 2 (n = 62) p
Tracer used for SLN mapping, n (%) 0.007
99mTc 2 (22.2) 2 (3.2)
99mTc ? blue dye 4 (44.4) 24 (38.7)
ICG 3 (33.3) 36 (58.1)
Detection rate n (%) 0.0005
Overall detection 6 (66.6) 59 (95.1) 0.02
Unilateral detection 3 (33.3) 5 (8.1)a 0.05
Bilateral detection 3 (33.3) 54 (87.0) 0.0001
No detection 3 (33.3) 3 (4.9) 0.02
Number positive SLNs 0 14
Number positive NSLNs 1 13
False-negative rate 0 0
NPV 100 100
Number SLNs, median (range) 1 (0–4) 3 (0–15) 0.015
Number NSLNs, median (range) 33 (24–46) 34.5 (0–80) 0.03
Location of SLNs, % NS
Obturator fossa 33.3 58 0.76
External iliac artery 50 17 0.23
Common iliac artery 8.3 19 0.7
Para-aortic region 8.3 6 0.54
SLN sentinel lymph node, 99mTc technetium-99m, ICG indocyanine green, NSLN non–sentinel lymph node, NPV negative predictive value
a In 1 patient, SLN identification was unilateral due to positivity of SLN; the opposite side was not evaluated
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99mTc and blue dye combined.33 Although in our study
patients in group 1 were significantly more often mapped
with 99mTc alone and significantly less with ICG compared
to group 2, we believe that postsurgical anatomic distortion
rather that these differences resulted in the reduced
detection rates. However, it can be speculated that per-
forming ICG SLN mapping may increase detection rates in
this scenario as well.
The location of the SLNs is consistent with those
reported in larger cervical cancer series and is mainly along
the external or internal iliac nodal basins.34 In a few cases,
SLNs are localized along the common iliac vessels or at the
aortic bifurcation. No unusual or aberrant SLN locations
were recorded, further confirming that tracer injection in
the vaginal vault is a valid surrogate for the cervix in this
setting; despite postoperative scarring, the lymphatic drai-
nage of the vaginal cuff is sufficient to allow for a SLN
identification in a large number of patients. In our series,
the negative predictive value of SLN mapping was 100 %
in both groups. In other words, if a SLN was identified and
was negative for metastases at final pathologic analysis, all
other lymph nodes were also negative.
Limitations of the study include the small number of
patients with occult cervical cancer and the variety of
tracers used. Occult cervical cancer is a relatively
uncommon finding, and the long interval of time during
which these patients were treated explains the differences
in the tracers used. Strengths of the study include a com-
parison with a large number of SLN mapping in cervical
cancer patients and the large median number of lymph
nodes removed, providing sensitivity for the SLN mapping.
Although feasible and accurate, SLN mapping in occult
cervical cancer patients has lower overall and bilateral
detection rates compared to patients undergoing SLN
mapping with their uterus in situ. Patients with occult
cervical cancer diagnosed on a simple hysterectomy spec-
imen represent a cohort of patients in whom a proper
management of their disease has already failed before
diagnosis, and in whom every additional mistake may
compromise the curative intent of treatment. We believe
that in this subset of patients, SLN mapping should be used
cautiously in clinical practice. When adopted, it should be
used in conjunction with a SLN mapping protocol that
recommends the excision of any suspicious lymph nodes
and the performance of a full lymphadenectomy in non-
mapping hemipelvises.35
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